Skip to main content

Table 3 Number (n/tot) and percentage (%) of dogs infected with Capillaria aerophila and/or Capillaria boehmi showing one or more clinical signs related to upper/lower respiratory tract on Day 0, Day 28 and Day 56

From: Efficacy of milbemycin oxime/afoxolaner chewable tablets (NEXGARD SPECTRA®) against Capillaria aerophila and Capillaria boehmi in naturally infected dogs

Clinical sign Group Day 0 Day 28 Day 56
Sneezing 1 1/25 1/25 1/25
2 3/26 0/26 0/26
Reverse sneezing 1 1/25 1/25 1/25
2 0/26 1/26 0/26
Nasal discharge 1 0/25 0/25 0/25
2 4/26 3/26 0/26
Bronchovesicular sounds 1 0/25 0/25 2/25
2 3/26 0/26 0/26
Chronic dry cough 1 4/25 4/25 4/25
2 7/26 2/26 1/26
Dry cough 1 0/25 0/25 1/26
2 0/26 0/26 0/26
Number of dogs with at least one clinical sign 1 6/25 (24%) 6/25 (24%) 8/25 (32%)
2 13/26 (50.0%) 6/26 (23.1%) 1/26 (3.8%)
  1. Group 1: dogs treated with the negative control product NEXGARD®
  2. Group 2: dogs treated with NEXGARD SPECTRA®